3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
43
Neoplasm Metastasis
5
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Brain Neoplasms
3
Stomach Neoplasms
2
Salivary Gland Neoplasms
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Neoplasms
2
HER2-positive Breast Cancer
2
Urologic Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thrombocytosis
1
Sarcoma
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pathologic Complete Response
1
Ovarian Neoplasms
1
Neoplasm, Residual
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Metastatic HER2-positive Breast Cancer With Brain Metastasis
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Interventions
Echocardiography
4
sacubitril and valsartan sodium hydrate drug combination
3
Standard of Care
3
Nutrition Assessment
3
Exercise
3
Electrocardiography
3
Carvedilol
3
dapagliflozin
2
Surveys and Questionnaires
2
Spironolactone
2
Ivabradine
2
Blood Specimen Collection
2
Atorvastatin
2
ziprasidone
1
pertuzumab
1
pegfilgrastim
1
nicotinamide-beta-riboside
1
empagliflozin
1
candesartan
1
Zolpidem
1
Watchful Waiting
1
Warfarin
1
Vincristine
1
Vecuronium Bromide
1
Vascular Stiffness
1
Vancomycin
1
Valsartan
1
Trastuzumab
1
Tranexamic Acid
1
Tobramycin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Heart Failure
×
Ado-Trastuzumab Emtansine
×
Clear all
NCT04680442
2025-04-06
SCHOLAR-2
Population Health Research Institute
Phase 2
Recruiting
130 enrolled